自适应质子治疗在头颈癌中的剂量学影响——综述
本综述检索2010年1月至2022年3月PubMed/MEDLINE、EMBASE和Web of Science文献,最终纳入10篇,评估自适应质子治疗(APT)在头颈癌调强质子治疗(IMPT)中的剂量学影响及计划适配时机。纳入研究报告IMPT计划靶区覆盖在放疗疗程中下降,应用APT后恢复;APT使高剂量和低剂量靶区D98分别最高改善2.5 Gy(3.5%)和4.0 Gy(7.1%),危及器官剂量持平或略降;APT多执行一次,最佳时机尚未确定。
要点
- IMPT治疗头颈癌期间靶区覆盖会下降,应用APT可恢复靶区覆盖。
- APT使高剂量靶区D98最高改善2.5 Gy(3.5%),低剂量靶区D98最高改善4.0 Gy(7.1%)。
- APT后危及器官剂量持平或略降,最佳APT时机尚未确定。
核心结论
- 头颈癌患者IMPT期间应用APT可改善靶区覆盖;单次自适应干预带来的靶区覆盖改善最大,后续第二次或更频繁的APT可进一步改善靶区覆盖;APT后危及器官剂量持平或略降;APT的最佳时机尚未确定。
研究设计与样本
- 本综述检索PubMed/MEDLINE、EMBASE和Web of Science从2010年1月至2022年3月发表的文献,共评估59条记录,最终纳入10篇文章。
主要发现
- 纳入研究报告IMPT计划在放疗疗程中靶区覆盖下降,应用APT方法后恢复。
- 所有APT计划与计划方案上的累积剂量相比,高剂量和低剂量靶区的平均靶区覆盖均改善。
- APT使高剂量靶区D98最高改善2.5 Gy(3.5%),低剂量靶区D98最高改善4.0 Gy(7.1%)。
- 应用APT后危及器官剂量持平或略降。
- 纳入研究中APT大多执行一次,带来最大的靶区覆盖改善,但后续额外APT进一步改善靶区覆盖;无数据显示APT最适时机。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出尚无数据显示APT最合适的时机。
- 原文指出APT的最佳时机尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intensity Modulated Proton Therapy (IMPT) in head and neck cancer (HNC) is susceptible to anatomical changes and patient set-up inaccuracies during the radiotherapy course, which can cause discrepancies between planned and delivered dose. The discrepancies can be counteracted by adaptive replanning strategies. This article reviews the observed dosimetric impact of adaptive proton therapy (APT) and the timing to perform a plan adaptation in IMPT in HNC. METHODS: A literature search of articles published in PubMed/MEDLINE, EMBASE and Web of Science from January 2010 to March 2022 was performed. Among a total of 59 records assessed for possible eligibility, ten articles were included in this review. RESULTS: Included studies reported on target coverage deterioration in IMPT plans during the RT course, which was recovered with the application of an APT approach. All APT plans showed an average improved target coverage for the high- and low-dose targets as compared to the accumulated dose on the planned plans. Dose improvements up to 2.5 Gy (3.5 %) and up to 4.0 Gy (7.1 %) in the D98 of the high- and low dose targets were observed with APT. Doses to the organs at risk (OARs) remained equal or decreased slightly after APT was applied. In the included studies, APT was largely performed once, which resulted in the largest target coverage improvement, but eventual additional APT improved the target coverage further. There is no data showing what is the most appropriate timing for APT. CONCLUSION: APT during IMPT for HNC patients improves target coverage. The largest improvement in target coverage was found with a single adaptive intervention, and an eventual second or more frequent APT application improved the target coverage further. Doses to the OARs remained equal or decreased slightly after applying APT. The most optimal timing for APT is yet to be determined.
引用
- Huiskes M, Astreinidou E, Kong W, et al. Dosimetric impact of adaptive proton therapy in head and neck cancer - A review. Clin Transl Radiat Oncol. 2023. PMID: 36860581. doi:10.1016/j.ctro.2023.100598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。